Alzheimer's drug flunks in 1 of 2 populations, Pfizer says
July 24 2012
A closely watched Alzheimer's compound being co-developed by Pfizer failed to show efficacy in one of several Phase III trials.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.